Sinovac pharmaceutical industry layout renews efforts to explore synthetic biotechnology

On November 2, Sinovac Pharmaceutical (stock code: 688136) announced that the company signed a strategic cooperation agreement with the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences (hereinafter referred to as "Tiangong Institute"), Chinese Academy of Sciences, to carry out all-round and multi-level cooperation
in the research and development of synthetic biotechnology, the transformation of high-tech achievements and talent training.

This is another strategic layout under the market and policy-oriented layout of Sinovac Pharmaceutical, which is guided by the two-wheel drive platform development model of "innovation + internationalization" in recent years, focusing on the mining of long-term value, actively seeking breakthroughs in the field of cutting-edge biotechnology, and cultivating new industries - market- market- and policy-oriented, layout synthetic biology business
in the field of big health.

Synthetic biotechnology is the frontier research direction in the field of biology today, and compared with traditional chemical synthesis, synthetic biotechnology has the characteristics of
green environmental protection, environmental friendliness, low energy consumption, low cost and high safety.
Therefore, synthetic biotechnology is gradually replacing traditional chemical synthesis and becoming an important way of "green synthesis" in the fields of medicine, food, materials and other fields around the world, and has been widely used in biomedicine, green agriculture, nutrition and health, new materials, energy conservation and emission reduction and other fields
.

For example, synthetic biotechnology can help explore the key genetic elements of animal and plant nutrition and functional component synthesis, optimize and coordinate the expression of various proteins in the synthetic pathway, build new cell factories, and subvert the existing food production and processing methods; For example, the use of synthetic biotechnology can help improve agricultural productivity, improve crops, reduce production costs, etc.
, and at the same time can modify plant photosynthesis to increase agricultural yield, use microorganisms or metabolic engineering means to reduce the use of agricultural fertilizers, and reshape metabolic pathways to improve crops, bringing breakthrough growth in agricultural product capacity and nutritional value
.

In recent years, synthetic biotechnology has attracted much attention
from the industry.
Domestic support for related industries is also increasing
.
In 2020, the National Development and Reform Commission proposed to support the construction of synthetic biology technology innovation centers in the Guiding Opinions on Expanding Investment in Strategic Emerging Industries to Cultivate and Expand New Growth Points, and the governments of Beijing, Jiangsu, Shenzhen, Shanghai, Tianjin and other places have successively issued policies
to support the development of the synthetic biotechnology industry.

According to the "Synthetic Biology Global Market Report 2022", the global market size of synthetic biology has reached 10.
07 billion US dollars in 2021, and the global synthetic biology market is expected to reach 33.
63 billion US dollars by 2026, with a compound annual growth rate of 27.
27%
from 2021 to 2026.

At present, the domestic synthetic biology industry has not yet achieved large-scale industrial application, the market pattern has not yet formed, for high-growth enterprises, the layout of synthetic biotechnology track, the future will achieve broader development prospects
.
Enterprises that can achieve gene editing to product landing, both synthetic biotechnology reserves and market-oriented product landing capabilities, are more likely to achieve leapfrog development
in the future.
For Sinovac, synthetic biotechnology is a new field and new industry
for the company's forward-looking layout.

The Institute of Tiangong of the Chinese Academy of Sciences is a scientific research institution jointly established by the Chinese Academy of Sciences and the Tianjin Municipal People's Government to engage in biotechnology innovation to promote ecological development in the industrial field, and is the Institute of Sequence Studies of the Chinese Academy of
Sciences.
The Institute of Tiangong of the Chinese Academy of Sciences has a synthetic biotechnology platform and has strong R&D strength
in the fields of life science and biotechnology.

According to the announcement, Sinovac Pharmaceutical established a wholly-owned subsidiary, Shenzhen Sinovac Tianhe Biotechnology Co.
, Ltd.
, to engage in the research and development of synthetic biotechnology and the transformation of
achievements.
This cooperation can be said to officially open a new era
of Sinovac pharmaceutical biotechnology.

Sinovac Pharmaceutical is an innovative biopharmaceutical enterprise mainly engaged in the research and development, production and sales of recombinant protein drugs and microecological preparations, after years of R&D technology accumulation, has formed three biotechnology systems of eukaryotic cell technology, prokaryotic cell technology and microecological live bacteria technology, strain technology platform, recombinant protein secretion and expression platform and other core technology and process platforms, which can empower the gene design, strain modification, product functional property identification, isolation and purification of synthetic biology and other research and development, process development and other links
。 At the same time, years of industrialization experience in recombinant proteins and microecological preparations also enable Sinovac to have the ability of quality control, cost control and process optimization of microbial fermentation products, and can undertake the industrialization
of synthetic biology.

Sinovac Pharmaceutical said that for the company's new business, on the basis of doing a good job in its own main business, relying on the existing pharmaceutical biotechnology platform and process development and industrialization capabilities, taking the market and policy as the guide, and laying out synthetic biology business in the field of general health, in line with the company's strategic development plan
.